Abstract
Overview
Introduction
At the forefront of novel technologies; momentum is steadily building for the
development of stem cell products to address cardiovascular disease. The most
active areas are those with high clinical unmet need heart failure,
cardiomyopathy and ishemic heart disease.
Scope
- Analysis of the current unmet needs in cardiovascular disease markets
- Opinion leader commentary on key clinical trials and market landscape
- Review of the clinical and commercial status of stem cell therapy for
cardiovascular disease
- Review of the clinical and commercial status of gene therapy for
cardiovascular disease
Highlights
Datamonitor' s analysis demonstrates how the most innovative drugs offer the
greatest growth potential for their respective markets. In the mature
cardiovascular market, commercial success must be derived from innovative
approaches with unique clinical benefits.
The array of innovative gene and cell products emerging from young companies
exposes investment opportunities for venture capitalists, Big Pharma, as well
as partnering opportunities for technology companies that can offer compatible
catheters, or cell delivery devices.
There awaits an outstanding commercial opportunity for innovators who address
clinical unmet need in this market, as a number of companies will see their
key revenue generators melt away as they lose patent protection.
Reasons to Purchase
- Understand the need for innovation in the cardiovascular market.
- Up to date insight into the commercial and clinical status of
cardiovascular gene and cell therapies
- Understand the barriers to commercialization of novel therapies, with
expert commentary
View Cart
